ATE340570T1 - 3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff and pharmaceutische formulatierungen davon - Google Patents

3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff and pharmaceutische formulatierungen davon

Info

Publication number: ATE340570T1
Authority: AT; Austria
Prior art keywords: pharmaceutical formulations; triiodothyronine; thyromimetic; triiodothyronine sulfate; sulfate
Prior art date: 2002-11-13

Application number

AT03767529T

Other languages

English (en)

Inventor

Aldo Pinchera

Ferruccio Santini

Original Assignee

Bracco Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-13

Filing date

2003-11-11

Publication date

2006-10-15

2003-11-11 Application filed by Bracco Spa filed Critical Bracco Spa

2006-10-15 Application granted granted Critical

2006-10-15 Publication of ATE340570T1 publication Critical patent/ATE340570T1/de

Links

XBQYQXVJBNDCGY-LBPRGKRZSA-N 3,3',5-triiodo-L-thyronine sulfate Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(OS(O)(=O)=O)C(I)=C1 XBQYQXVJBNDCGY-LBPRGKRZSA-N 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
230000000929 thyromimetic effect Effects 0.000 title abstract 2
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 abstract 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000007170 pathology Effects 0.000 abstract 1
229940034208 thyroxine Drugs 0.000 abstract 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
- G01N33/561—Immunoelectrophoresis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Inorganic Chemistry (AREA)
Diabetes (AREA)
Plasma & Fusion (AREA)
Electrochemistry (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT03767529T 2002-11-13 2003-11-11 3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff and pharmaceutische formulatierungen davon ATE340570T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ITMI20022394 ITMI20022394A1 (it)	2002-11-13	2002-11-13	Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.

Publications (1)

Publication Number	Publication Date
ATE340570T1 true ATE340570T1 (de)	2006-10-15

Family

ID=32310157

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03767529T ATE340570T1 (de)	2002-11-13	2003-11-11	3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff and pharmaceutische formulatierungen davon

Country Status (13)

Country	Link
US (5)	US9012438B2 (de)
EP (2)	EP1767202A1 (de)
JP (2)	JP5301074B2 (de)
CN (2)	CN1711079A (de)
AT (1)	ATE340570T1 (de)
AU (1)	AU2003292006A1 (de)
CY (1)	CY1107312T1 (de)
DE (1)	DE60308718T2 (de)
DK (1)	DK1560575T3 (de)
ES (1)	ES2273045T3 (de)
IT (1)	ITMI20022394A1 (de)
PT (1)	PT1560575E (de)
WO (1)	WO2004043452A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012136761A1 (en) *	2011-04-08	2012-10-11	Bracco Imaging Spa	Process for the preparation of a sulfated derivative of 3,5-diiodo-o-[3-iodophenyl]-l-tyrosine
ITMI20110713A1 (it) *	2011-04-29	2012-10-30	Bracco Imaging Spa	Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it)	2002-11-13	2004-05-14	Bracco Spa	Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
GB0525461D0 (en) *	2005-12-15	2006-01-25	Archimedes Dev Ltd	Pharmaceutical compositions
US20120178813A1 (en)	2011-01-12	2012-07-12	Thetis Pharmaceuticals Llc	Lipid-lowering antidiabetic agent
CN102507919A (zh) *	2011-11-08	2012-06-20	江苏省原子医学研究所	一种标记3,3’-二碘甲腺氨酸硫酸化物的方法及检测试剂盒
WO2015171516A1 (en)	2014-05-05	2015-11-12	Thetis Pharmaceuticals Llc	Compositions and methods relating to ionic salts of peptides
US9242008B2 (en)	2014-06-18	2016-01-26	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of fatty acids
CN107074884A (zh)	2014-06-18	2017-08-18	西蒂斯制药有限责任公司	活性剂的矿物质氨基酸复合物
JP6906047B2 (ja)	2016-06-03	2021-07-21	テティス・ファーマシューティカルズ・エルエルシー	特異的炎症収束性メディエーターの塩に関連する組成物及び方法
JP6968603B2 (ja) *	2017-07-10	2021-11-17	キヤノン株式会社	画像形成装置、画像形成方法、プログラム
CA3103732A1 (en) *	2018-07-13	2020-01-16	Aegirbio Ab	Biosensor for diagnosis of thyroid dysfunction
WO2024129551A1 (en) *	2022-12-16	2024-06-20	Merck Sharp & Dohme Llc	Solid dosage form of a small molecule antiviral and uses thereof
WO2025245024A1 (en) *	2024-05-20	2025-11-27	Regents Of The University Of Minnesota	Compositions comprising liothyronine and methods of making thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2993928A (en)	1957-01-15	1961-07-25	Glaxo Lab Ltd	Preparation of triiodothyronine
US2970165A (en)	1957-10-01	1961-01-31	Warner Lambert Pharmaceutical	Sulfate compounds
US3313839A (en)	1963-07-01	1967-04-11	Gen Aniline & Film Corp	Preparation of sulfate esters by the reaction of chlorosulfonic acid with alkoxylated alkyl phenols
US4031622A (en) *	1975-10-28	1977-06-28	Wells Manufacturing Corporation	Portable power driven implement
US4254095A (en) *	1978-04-27	1981-03-03	Research Corporation	Radioimmunoassay for erythropoietin
JPH07116031B2 (ja) *	1986-09-24	1995-12-13	株式会社アドバンス	制癌剤
US5116828A (en) *	1989-10-26	1992-05-26	Nippon Zoki Pharmaceutical Co., Ltd.	Pharmaceutical composition for treatment of osteoporosis
WO1991011181A1 (en)	1990-02-05	1991-08-08	British Technology Group (Usa) Incorporated	Thyroid hormone cardiac treatment
US5158978A (en)	1990-02-05	1992-10-27	British Technology Group (U.S.A.)	Thyroid hormone treatment of acute cardiovascular compromise
US5272078A (en) *	1991-01-29	1993-12-21	Brigham And Women's Hospital	CDNA encoding the type I iodothyronine 5'deiodinase
US6498037B1 (en)	1991-03-04	2002-12-24	Bayer Corporation	Method of handling reagents in a random access protocol
US5225204A (en)	1991-11-05	1993-07-06	Chen Jivn Ren	Stable dosage of levothyroxine sodium and process of production
DE69224809T2 (de)	1991-12-30	1998-07-09	Akzo Nobel Nv	Thyroaktive Zusammensetzung mit kontrollierter Freigabe
KR950010051Y1 (ko)	1993-10-15	1995-11-25	이해섭	휴대용 절첩테이블
GB9401892D0 (en)	1994-02-01	1994-03-30	Boots Co Plc	Therapeutic agents
DE19541128C2 (de)	1995-10-27	1997-11-27	Henning Berlin Gmbh & Co	Stabilisierte schilddrüsenhormonhaltige Arzneimittel
US5955105A (en)	1995-11-14	1999-09-21	Knoll Pharmaceutical Company	Stabilized thyroid hormone preparations and methods of making same
AU2679899A (en)	1998-02-18	1999-09-06	Dade Behring Inc.	Chemiluminescent compositions for use in detection of multiple analytes
DE19821625C1 (de)	1998-05-15	2000-01-05	Merck Patent Gmbh	Pharmazeutische Zubereitung
US6599942B1 (en) *	1999-03-29	2003-07-29	Novartis Ag	Thyromimetic organic compounds
US6740680B1 (en) *	1999-04-26	2004-05-25	Becton Pharma, Inc.	Pharmaceutical compositions to tetrac and methods of use thereof
US6664291B2 (en) *	2000-03-31	2003-12-16	Pfizer, Inc.	Malonamic acids and derivatives thereof as thyroid receptor ligands
EP1307741A4 (de) *	2000-07-26	2005-11-23	Biodiagnostics Inc	Verfahren zur diagnose von thyroidparametern und zum überwachen von thyroxintherapien
US7163918B2 (en) *	2000-08-22	2007-01-16	New River Pharmaceuticals Inc.	Iodothyronine compositions
US6979462B1 (en)	2000-10-03	2005-12-27	Mutual Pharmaceutical Co., Inc.	Stabilization of solid drug formulations
US6855333B1 (en)	2000-10-03	2005-02-15	Mutual Pharmaceutical Co., Inc.	Stabilization of solid thyroid drug formulations
US6555581B1 (en)	2001-02-15	2003-04-29	Jones Pharma, Inc.	Levothyroxine compositions and methods
BR0207297A (pt)	2001-02-15	2005-04-19	King Pharmaceuticals Inc	Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
US20030224047A1 (en)	2001-02-15	2003-12-04	Franz G. Andrew	Levothyroxine compositions and methods
ITMI20011401A1 (it)	2001-07-02	2003-01-02	Altergon Sa	Formulazioni farmaceutiche per ormoni tiroidei
DE10136615A1 (de)	2001-07-17	2003-02-06	Berlin Chemie Ag	Schilddrüsentherapeutika
US20030195253A1 (en)	2001-08-14	2003-10-16	Franz G. Andrew	Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US7101569B2 (en)	2001-08-14	2006-09-05	Franz G Andrew	Methods of administering levothyroxine pharmaceutical compositions
US20030099699A1 (en)	2001-11-13	2003-05-29	Hanshew Dwight D.	Storage stable thyroxine active drug formulations and methods for their production
ITMI20022394A1 (it)	2002-11-13	2004-05-14	Bracco Spa	Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it)	2011-04-29	2012-10-30	Bracco Imaging Spa	Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022777A1 (it)	2002-12-27	2004-06-28	Altergon Sa	Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento.
US20040156893A1 (en)	2003-02-11	2004-08-12	Irwin Klein	Method for treating hypothyroidism
US8293272B2 (en)	2003-05-02	2012-10-23	Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H.	Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
BRPI0410021A (pt)	2003-05-02	2006-04-25	Globopharm Pharmazeutische Pro	preparação farmacêutica sólida, que contém sais levotiroxina e/ou liotironina como substáncia ativa
GB0316206D0 (en)	2003-07-10	2003-08-13	Glaxo Group Ltd	Pharmaceutical formulation
EP1799196B1 (de)	2004-10-08	2016-06-22	Forward Pharma A/S	Pharmazeutische zusammensetzung mit kontrollierter freisetzung mit einem fumarsäureester
WO2007140189A2 (en)	2006-05-26	2007-12-06	Auspex Pharmaceuticals, Inc.	Preparation and utility of substituted carboxylic acid compounds
PT1958617E (pt)	2007-02-14	2010-10-28	Lesvi Laboratorios Sl	Composições farmacêuticas contendo fumarato de quetiapina
EP2148660A2 (de)	2007-04-23	2010-02-03	Diurnal Ltd	Verzögerte freisetzung
WO2008140459A1 (en)	2007-05-16	2008-11-20	Fmc Corporation	Solid form
EP1992341A1 (de)	2007-05-16	2008-11-19	Université Joseph Fourier	Neue pharmazeutische Zusammensetzungen mit einem Schilddrüsenhormon und ihre therapeutische Verwendung
FR2931359B1 (fr)	2008-05-20	2012-12-21	Menvielle Bourg Fabienne Joanny	Utilisation d'une matrice pour administration orale de magnesium a liberation prolongee, et composition contenant cette matrice
KR20210009441A (ko)	2009-04-01	2021-01-26	바이알 - 포르텔라 앤드 씨에이 에스에이	니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
CN102259831A (zh)	2010-05-27	2011-11-30	清华大学	三维纳米结构阵列

2002
- 2002-11-13 IT ITMI20022394 patent/ITMI20022394A1/it unknown
2003
- 2003-11-11 AT AT03767529T patent/ATE340570T1/de active
- 2003-11-11 DK DK03767529T patent/DK1560575T3/da active
- 2003-11-11 PT PT03767529T patent/PT1560575E/pt unknown
- 2003-11-11 EP EP20060117480 patent/EP1767202A1/de not_active Withdrawn
- 2003-11-11 EP EP03767529A patent/EP1560575B1/de not_active Expired - Lifetime
- 2003-11-11 ES ES03767529T patent/ES2273045T3/es not_active Expired - Lifetime
- 2003-11-11 CN CNA2003801030574A patent/CN1711079A/zh active Pending
- 2003-11-11 US US10/532,447 patent/US9012438B2/en not_active Expired - Fee Related
- 2003-11-11 AU AU2003292006A patent/AU2003292006A1/en not_active Abandoned
- 2003-11-11 WO PCT/EP2003/012584 patent/WO2004043452A1/en not_active Ceased
- 2003-11-11 CN CNA2008101357627A patent/CN101406467A/zh active Pending
- 2003-11-11 JP JP2004550983A patent/JP5301074B2/ja not_active Expired - Fee Related
- 2003-11-11 DE DE2003608718 patent/DE60308718T2/de not_active Expired - Lifetime
2006
- 2006-11-14 CY CY061101656T patent/CY1107312T1/el unknown
2010
- 2010-12-24 JP JP2010288189A patent/JP2011102306A/ja active Pending
2011
- 2011-04-08 US US13/083,047 patent/US20110245342A1/en not_active Abandoned
2013
- 2013-01-31 US US13/755,279 patent/US9044441B2/en active Active
- 2013-06-13 US US13/916,710 patent/US9468619B2/en active Active
2016
- 2016-09-21 US US15/271,355 patent/US10238615B2/en active Active

Also Published As

Publication number	Publication date
DK1560575T3 (da)	2007-01-29
ITMI20022394A1 (it)	2004-05-14
CN1711079A (zh)	2005-12-21
WO2004043452A1 (en)	2004-05-27
PT1560575E (pt)	2007-01-31
US20050272816A1 (en)	2005-12-08
US20130146502A1 (en)	2013-06-13
EP1560575A1 (de)	2005-08-10
DE60308718T2 (de)	2007-08-02
EP1560575B1 (de)	2006-09-27
JP5301074B2 (ja)	2013-09-25
AU2003292006A1 (en)	2004-06-03
US9468619B2 (en)	2016-10-18
US10238615B2 (en)	2019-03-26
US9012438B2 (en)	2015-04-21
CY1107312T1 (el)	2012-11-21
CN101406467A (zh)	2009-04-15
DE60308718D1 (de)	2006-11-09
JP2011102306A (ja)	2011-05-26
EP1767202A1 (de)	2007-03-28
US20130281536A1 (en)	2013-10-24
US20170007563A1 (en)	2017-01-12
US20110245342A1 (en)	2011-10-06
US9044441B2 (en)	2015-06-02
JP2006508956A (ja)	2006-03-16
ES2273045T3 (es)	2007-05-01

Legal Events

Date

Code

Title

Description

2007-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1560575

Country of ref document: EP

Publication	Publication Date	Title
ATE340570T1 (de)	2006-10-15	3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff and pharmaceutische formulatierungen davon
BR0313371A (pt)	2005-07-05	Composto, uso de um composto e método de tratamento de doença
GB0225474D0 (en)	2002-12-11	Therapeutic agents
GB0223038D0 (en)	2002-11-13	Therapeutic compounds
BR0317696A (pt)	2005-11-22	Composição para branqueamento
CY1111867T1 (el)	2015-11-04	Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη
ATE514418T1 (de)	2011-07-15	Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
ATE260650T1 (de)	2004-03-15	Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
UA100966C2 (ru)	2013-02-25	Фармацевтическая композиция на основе 2-[4-(4-хлорбензоил)фенокси]-2-метилпропионовой кислоты и ее солей
DK0694545T3 (da)	2000-09-18	Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder
BR0112770A (pt)	2003-06-24	Agentes herbicidas
BR0312683A (pt)	2005-04-26	Cápsulas de higiene oral
ATE319467T1 (de)	2006-03-15	Formulierungen zur behandlung von männlicher und weiblicher impotenz
EP1781277A4 (de)	2008-09-03	Kombinationspräparat
DE602004023762D1 (de)	2009-12-03	Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
BR0316796A (pt)	2005-11-01	Processos para redução da concentração de mehq em ácido acrìlico e para preparação de superabsorventes
UY27373A1 (es)	2003-02-28	Formulaciones de interferón beta-humano
CY1111900T1 (el)	2015-11-04	Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα ν-μεθυλ-d-ασπαρτικων (nmda)
NO20013544L (no)	2002-01-21	Middel for å behandle Parkinsons sykdom samt anvendelse derav
BRPI0511125A (pt)	2007-11-27	usos de ácido 5,6,7-triidroxieptanóico seus e análogos
BRPI0409586A (pt)	2006-04-18	ácidos hidroxámicos úteis no tratamento de distúrbios hiperproliferativos
TR199500984A2 (tr)	1996-06-21	Selegilin'in epileptik hastaliklarin tedavisinde kullanimi.
FI20030379A0 (fi)	2003-03-14	Uusi farmaseuttinen koostumus
BRPI0415428A (pt)	2006-12-05	formulações terapêuticas
DE60327249D1 (de)	2009-05-28	Anthranilsäureamide und ihre pharmazeutische verwendung